Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the invention relates to tetrahydropyridothiophene derivatives, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions.
• the invention further relates to the contribution made to the art by the finding, that said tetrahydropyridothiophene derivatives display cell-cycle dependent, anti-proliferative and apoptosis inducing activity.
• the invention also relates to the use of these tetrahydropyridothiophene derivatives for the therapy of hyperproliferative diseases, in particular human cancer.
• RNA/DNA alkylating and carbamylating agents, platin analogs and topoisomerase inhibitors
• metabolism drugs of this class are named anti-metabolites and examples are folic acid, purin and pyrimidine antagonist
• mitotic spindle apparatus with ⁇ -tubulin heterodimers as the essential component
• drugs are categorized into stabilizing and destabilizing tubulin inhibitors; examples are Taxol/ Paclitaxel®, Docetaxel/Taxotere® and vinca alkaloids).
• a subgroup of proapoptotic anticancer agents target cells preferentially in mitosis. In general these agents do not induce apoptosis in non-dividing cells, arrested in the GO, G1 or G2 phase of the cell division cycle. In contrast, dividing cells going through mitosis (M-phase of the cell division cycle), are killed efficiently by induction of apoptosis by this subgroup agents. Therefore, this subgroup or class of anti-cancer agents is described as cell-cycle specific or cell-cycle dependent.
• Tubulin inhibitors with Taxol (Paclitaxel®) as a prominent example, belong to this class of cell-cycle specific, apoptosis inducing anti-cancer agents.
• the german document DE4039734 describes, inter alia, N-alkylated tetrahydropyridothiophene derivatives as components of herbicidal agents.
• the german document DD272078 describes, inter alia, N-alkylated tetrahydropyridothiophene derivatives with antianaphylactic und antihistaminergic properties.
• the international application WO2005/033102 describes thiophene-based compounds exhibiting ATP- utilizing enzyme inhibitory activity.
• the international application WO2005/060711 describes a method of treating diseases mediated by sirtuin, e.g. SirT1 mediated deacetylation, using substituted thiophene compounds.
• the international application WO2005/033102 describes a method of combating phytopathogenic diseases on plants using 2-aminothiophene derivatives.
• the compounds according to this invention are potent and highly efficacious inhibitors of cellular (hyper)proliferation and/or cell-cycle specific inducers of apoptosis in cancer cells. Therefore, unanticipatedly, these compounds can be useful for treating (hyper)proliferative diseases and/or disorders responsive to the induction of apoptosis, in particular cancer.
• these derivates should have a higher therapeutic index compared to standard chemotherapeutic drugs targeting basic cellular processes like DNA replication or interfering with basic cellular molecules like DNA.
• the compounds according to this invention are expected to be useful in targeted cancer therapy.
• the invention thus relates, in a first aspect (aspect a), to compounds of formula I
• Ra is -C(O)ORI , in which
• R1 is 1-7C-alkyl, 3-7C-cycloalkyl, or 1-7C-alkyl substituted by one to four substituents independently selected from R2, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and either
• Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl or naphthyl, or
• Q is optionally substituted by Rca and/or Rcb, and is Har, or
• Q is optionally substituted by Rda and/or Rdb, and is Het, or
• Q is optionally substituted by Rea and/or Reb, and is 3-7C-cycloalkyl
• each R2 may be the same or different and is independently selected from the group consisting of: 1-4C-alkyl, 3-7C-cycloalkyl, phenyl, Har, Het, halogen, trifluoromethyl, nitro, cyano,
• each R3, R4, R5 and R6 may be the same or different and is each independently selected from the group consisting of: hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, phenyl, and phenyl-1-4C-alkyl,
• each R7 may be the same or different and is independently selected from the group consisting of: hydrogen, 1-7C-alkyl, and 3-7C-cycloalkyl,
• each R8 and R9 may be the same or different and is each independently selected from the group consisting of: hydrogen, and 1-4C-alkyl,
• each R10 may be the same or different is independently selected from the group consisting of: 1-4C-alkyl, phenyl, halogen, trifluoromethyl, cyano,
• each of said phenyl and phenoxy radicals can be unsubstituted or optionally substituted by up to four halogen radicals and up to two 1-4C-alkyl, hydroxyl, trifluoromethyl or cyano radicals,
• each y is 1 , 2, 3 or 4,
• each Rba, Rbb, Rbc, Rca, Rcb, Rda, Rdb, Rea and Reb may be the same or different and is each independently selected from the group consisting of: 1-4C-alkyl, phenyl, halogen, trifluoromethyl, cyano, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, and phenoxy, wherein each of said phenyl and phenoxy can be unsubstituted or optionally substituted by up to four halogen radicals and up to two 1-4C-alkyl, hydroxyl, trifluoromethyl or cyano radicals,
• each Har is the same or different and is independently any fully aromatic or partially aromatic mono- or fused bicyclic ring or ring system made up of a first constituent being a 5- or 6-membered monocyclic unsaturated, aromatic heteroaryl ring A, which heteroaryl ring A comprises one to four heteroatoms independently selected from nitrogen, oxygen and sulfur, and, optionally, fused to said first constituent, a second constituent being a benzene ring, a 5-6C-cycloalkane ring, an additional heteroaryl ring A as defined herein afore, or a heterocyclic ring B as defined herein below, whereby said Har ring or ring system is attached to the parent molecular group via a substitutable ring carbon or ring nitrogen atom,
• each Het is the same or different and is independently any fully saturated or partially unsaturated mono- or fused bicyclic ring or ring system made up of a first constituent being a 3- to 7-membered monocyclic fully saturated or partially unsaturated, non- aromatic heterocyclic ring B, which heterocyclic ring B comprises one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, and which heterocyclic ring B is optionally substituted by one or two oxo groups, and, optionally, fused to said first constituent, a second constituent being a benzene ring, a 3-7C-cycloalkane ring, or an additional heterocyclic ring
• the invention further relates in a second aspect (aspect b), which is an embodiment of aspect a, to compounds of formula I wherein
• Ra is -C(O)ORI , in which
• R1 is 1-7C-alkyl substituted by R20 and optionally by one to three further substituents independently selected from R2, Rb is -T-Q, in which
• T is 1-6C-alkylene or 3-7C-cycloalkylene, and either
• Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl or naphthyl, or
• Q is optionally substituted by Rca and/or Rcb, and is Har, or
• Q is optionally substituted by Rda and/or Rdb, and is Het, or Q is optionally substituted by Rea and/or Reb, and is 3-7C-cycloalkyl,
• R20 is selected from guanidino, hydroxy-2-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, pyridyl-1-4C-alkoxy, (1-4C-alkoxy-2- 4C-alkoxy)-2-4C-alkoxy, and completely or predominantly fluorine-substituted 1-4C-alkoxy, under the provisio that R20 is not trifluoromethoxy,
• each R2 may be the same or different and is independently selected from the group consisting of: 1-4C-alkyl, 3-7C-cycloalkyl, phenyl, Har, Het, halogen, trifluoromethyl, nitro, cyano,
• each R3, R4, R5 and R6 may be the same or different and is each independently selected from the group consisting of: hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, phenyl, and phenyl-1-4C-alkyl
• each R7 may be the same or different and is independently selected from the group consisting of: hydrogen, 1-7C-alkyl, and 3-7C-cycloalkyl
• each R8 and R9 may be the same or different and is each independently selected from the group consisting of: hydrogen, and 1-4C-alkyl
• each R10 may be the same or different is independently selected from the group consisting of:
• each of said phenyl and phenoxy radicals can be unsubstituted or optionally substituted by up to four halogen radicals and up to two 1-4C-alkyl, hydroxyl, trifluoromethyl or cyano radicals, each y is 1 , 2, 3 or 4, each Rba, Rbb, Rbc, Rca, Rcb, Rda, Rdb, Rea and Reb may be the same or different and is each independently selected from the group consisting of:
• each Har is the same or different and is independently any fully aromatic or partially aromatic mono- or fused bicyclic ring or ring system made up of a first constituent being a 5- or 6-membered monocyclic unsaturated, aromatic heteroaryl ring A, which heteroaryl ring A comprises one to four heteroatoms independently selected from nitrogen, oxygen and sulfur, and, optionally, fused to said first constituent, a second constituent being a benzene ring, a 5-6C-cycloalkane ring, an additional heteroaryl ring A as defined herein afore, or a heterocyclic ring B as defined herein below, whereby said Har ring or ring system is attached
• each Het is the same or different and is independently any fully saturated or partially unsaturated mono- or fused bicyclic ring or ring system made up of a first constituent being a 3- to 7-membered monocyclic fully saturated or partially unsaturated, non- aromatic heterocyclic ring B, which heterocyclic ring B comprises one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, and which heterocyclic ring B is optionally substituted by one or two oxo groups, and, optionally, fused to said first constituent, a second constituent being a benzene ring, a 3-7C-cycloalkane ring, or an additional heterocyclic ring
• the invention further relates in a third aspect (aspect c), which is also an embodiment of aspect a, to compounds of formula I wherein
• Ra is -C(O)ORI , in which
• R1 is 1-7C-alkyl, 3-7C-cycloalkyl, or 1-7C-alkyl substituted by one to four substituents independently selected from R2, Rb is -T-Q, in which
• T is 1-6C-alkylene or 3-7C-cycloalkylene, and either
• Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl or naphthyl, or Q is optionally substituted by Rca and/or Rcb, and is Har, or
• Q is optionally substituted by Rda and/or Rdb, and is Het, or
• Q is optionally substituted by Rea and/or Reb, and is 3-7C-cycloalkyl
• each R2 may be the same or different and is independently selected from the group consisting of:
• each R3, R4, R5 and R6 may be the same or different and is each independently selected from the group consisting of: hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl, phenyl, and phenyl-1-4C-alkyl
• each R7 may be the same or different and is independently selected from the group consisting of: hydrogen, 1-7C-alkyl, and 3-7C-cycloalkyl
• each R8 and R9 may be the same or different and is each independently selected from the group consisting of: hydrogen, and 1-4C-alkyl
• each R10 may be the same or different is independently selected from the group consisting of:
• each of said phenyl and phenoxy radicals can be unsubstituted or optionally substituted by up to four halogen radicals and up to two 1-4C-alkyl, hydroxyl, trifluoromethyl or cyano radicals, each y is 1 , 2, 3 or 4, each Rba, Rbb, Rbc, Rca, Rcb, Rda, Rdb, Rea and Reb may be the same or different and is each independently selected from the group consisting of:
• 1-4C-alkoxycarbonyl carboxyl, hydroxyl, and phenoxy, wherein each of said phenyl and phenoxy can be unsubstituted or optionally substituted by up to four halogen radicals and up to two 1-4C-alkyl, hydroxyl, trifluoromethyl or cyano radicals,
• each Har is the same or different and is independently any fully aromatic or partially aromatic mono- or fused bicyclic ring or ring system made up of a first constituent being a 5- or 6-membered monocyclic unsaturated, aromatic heteroaryl ring A, which heteroaryl ring A comprises one to four heteroatoms independently selected from nitrogen, oxygen and sulfur, and, optionally, fused to said first constituent, a second constituent being a benzene ring, a 5-6C-cycloalkane ring, an additional heteroaryl ring A as defined herein afore, or a heterocyclic ring B as defined herein below, whereby said Har ring or ring system is attached to the parent molecular group via a substitutable ring carbon or ring nitrogen atom,
• each Het is the same or different and is independently any fully saturated or partially unsaturated mono- or fused bicyclic ring or ring system made up of a first constituent being a 3- to 7-membered monocyclic fully saturated or partially unsaturated, non- aromatic heterocyclic ring B, which heterocyclic ring B comprises one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, and which heterocyclic ring B is optionally substituted by one or two oxo groups, and, optionally, fused to said first constituent, a second constituent being a benzene ring, a 3-7C-cycloalkane ring, or an additional heterocyclic ring
• 1-4C-Alkyl is a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, and, particularly, the ethyl and methyl radicals.
• 1-5C-Alkyl is a straight-chain or branched alkyl radical having 1 to 5 carbon atoms. Examples are the pentyl, butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and methyl radicals.
• 1-7C-Alkyl is a straight-chain or branched alkyl radical having 1 to 7 carbon atoms.
• Examples are the heptyl, isoheptyl (5-methylhexyl), hexyl, isohexyl (4-methylpentyl), neohexyl (3,3-dimethylbutyl), pentyl, isopentyl (3-methylbutyl), neopentyl (2,2-dimethylpropyl), butyl, isobutyl, sec-butyl, tert-butyl, isopropyl, and, in particular, the propyl, ethyl and methyl radicals.
• 1-6C-Alkylene is a straight chain or branched alkylene radical having 1 to 4 carbon atoms.
• Examples which may be mentioned in this context are the methylene (-CH 2 -), ethylene (-CH 2 -CH 2 -), trimethylene (-CH 2 -CH 2 -CH 2 -), tetramethylene (-CH 2 -CH 2 -CH 2 -CH 2 -), 1 ,2-dimethylethylene [-CH(CH 3 )-CH(CH 3 )-], 1 ,1-dimethylethylene [-C(CH 3 ) 2 -CH 2 -], 2,2-dimethylethylene [-CH 2 -C(CH 3 ) 2 -], isopropylidene [-C(CH 3 J 2 -], 1-methylethylene radical [-CH(CH 3 )-CH 2 -], 2-methylethylene radical [-CH 2 -CH(CH 3 )-], pentamethylene (-CH 2 -CH 2 -CH 2 -CH 2
• 3-7C-Cycloalkyl stands for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, of which cyclopropyl and cyclopentyl are to be emphasized.
• 3-7C-Cycloalkane stands for cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane, of which cyclohexane and cyclopentane are to be emphasized.
• 5-6C-Cycloalkane stands for cyclohexane and cyclopentane.
• 3-7C-Cycloalkylene represents cycloalkylene radicals having 3 to 7 carbon atoms, such as cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene and cycloheptylene, of which cyclopropylene is more worthy to be mentioned, where the 1 ,2-cyclopropylene radical is to be emphasized.
• Phenyl-1-4C-alkyl represents one of the abovementioned 1-4C-alkyl radicals, which is substituted by a phenyl radical. Examples which may be mentioned are the phenethyl and the benzyl radicals.
• Halogen within the meaning of the present invention is iodine, or, particularly, bromine, chlorine and fluorine.
• 1-4C-Alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy and methoxy radicals.
• 2-4C-Alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 2 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy radical.
• fluorine-substituted 1-4C-alkoxy for example, the 2,2,3, 3,3-penta- fluoropropoxy, the perfluoroethoxy, the 1 ,2,2-trifluoroethoxy, in particular the 1 ,1 ,2,2-tetrafluoroethoxy, the 2,2,2-trifluoroethoxy, the trifluoromethoxy and preferably the difluoromethoxy radicals may be mentioned.
• "Predominantly" in this connection means that more than half of the hydrogen atoms of the 1-4C-alkoxy radicals are replaced by fluorine atoms.
• 1-4C-Alkoxy-2-4C-alkoxy represents 2-4C-alkoxy radicals, which are substituted by one of the abovementioned 1-4C-alkoxy radicals.
• Examples which may be mentioned are the methoxyethoxy, ethoxyethoxy and the isopropoxyethoxy radicals, particularly the 2-methoxyethoxy, 2-ethoxyethoxy and the 2-isopropoxyethoxy radicals.
• Phenyl-1-4C-alkoxy represents one of the abovementioned 1-4C-alkoxy radicals, which is substituted by a phenyl radical. Examples which may be mentioned are the phenethoxy and the benzyloxy radicals.
• Pyridyl-1-4C-alkoxy represents one of the abovementioned 1-4C-alkoxy radicals, which is substituted by a pyridyl radical. Examples which may be mentioned are the 2-pyridyl-ethoxy and the pyridylmethoxy radicals.
• Pyridyl-1-4C-alkyl represents one of the abovementioned 1-4C-alkyl radicals, which is substituted by a pyridyl radical. Examples which may be mentioned are the 2-pyridyl-ethyl and the pyridylmethyl radicals.
• Pyridyl includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl.
• (1-4C-Alkoxy-2-4C-alkoxy)-2-4C-alkoxy represents 2-4C-alkoxy radicals, which are substituted by one of the abovementioned 1-4C-alkoxy-2-4C-alkoxy radicals. Examples which may be mentioned are the 2-(2-methoxyethoxy)-ethoxy and the 2-(2-ethoxyethoxy)-ethoxy radicals.
• Hydroxy-2-4C-alkoxy represents 2-4C-alkoxy radicals, which are substituted by a hydroxyl group. Examples which may be mentioned are the 2-hydroxyethoxy and the 3-hydroxypropoxy radicals.
• 1-4C-Alkoxycarbonyl represents a radical which, in addition to the carbonyl group, contains one of the abovementioned 1-4C-alkoxy radicals. Examples which may be mentioned are the methoxycarbonyl, the ethoxycarbonyl and the tertbutoxycarbonyl radicals.
• mono- or di-1-4C-alkylamino radicals contain one or two of the abovementioned 1-4C-alkyl radicals.
• Di-1-4C-alkylamino is preferred and here, in particular, dimethyl-, diethyl- or diisopropylamino.
• Mono- or Di-1-4C-alkylaminocarbonyl radicals contain in addition to the carbonyl group one of the abovementioned mono- or di-1-4C-alkylamino radicals. Examples which may be mentioned are the N- methyl- the N,N-dimethyl-, the N-ethyl-, the N-propyl-, the N,N-diethyl- and the N- isopropylaminocarbonyl radical.
• An 1-4C-Alkylcarbonylamino radical is, for example, the propionylamino (C 3 H 7 C(O)NH-) and the acetylamino radical (CH 3 C(O)NH-).
• 1-4C-Alkylcarbonyloxy stands for a carbonyloxy group to which one of the abovementioned 1-4C-alkyl radicals is bonded.
• An example is the acetoxy radical (CH 3 C(O)-O-).
• 1-4C-Alkylcarbonyl is a carbonyl group to which one of the abovementioned 1-4C-alkyl radicals is bonded.
• An example is the acetyl radical (CH 3 CO-).
• Naphthyl includes naphthalen-1-yl and naphthalen-2-yl.
• Har stands for a fully aromatic or partially aromatic mono- or fused bicyclic ring or ring system made up of a first constituent being a 5- or 6-membered monocyclic unsaturated, aromatic heteroaryl ring A, which heteroaryl ring A comprises one to four heteroatoms independently selected from nitrogen, oxygen and sulfur, and, optionally, fused to said first constituent, a second constituent being a benzene ring, a 5-6C-cycloalkane ring, an additional heteroaryl ring A as defined herein afore, or a heterocyclic ring B as defined herein below in the context of the definition of Het, whereby said Har ring or ring system is attached to the parent molecular group via a substitutable ring carbon or ring nitrogen atom.
• Examples for Har may include, but are not limited to, 5-membered heteroaryl radicals, such as e.g. furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, thiadiazolyl or oxadiazolyl, and 6-membered heteroaryl radicals, such as e.g. pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, and the benzo-fused derivatives thereof such as e.g.
• 5-membered heteroaryl radicals such as e.g. furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, thiadiazoly
• quinazolinyl quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, indazolyl, phthalazinyl, benzothiophenyl, benzofuranyl, isobenzofuranyl, benzoxazolyl, benzothiazolyl or benzimidazolyl, as well as naphthyridinyl, indolizinyl or purinyl.
• Har When R2 is Har, a more detailed example for Har includes imidazolyl.
• Har When R2 is Har, a further more detailed example for Har includes imidazol-1-yl.
• R2 is Har
• another more detailed example for Har includes pyridinyl.
• a further more detailed example for Har includes pyridin-2-yl.
• another further more detailed example for Har includes pyridin-3-yl.
• another further more detailed example for Har includes pyridin-4-yl.
• Het stands for a fully saturated or partially unsaturated mono- or fused bicyclic ring or ring system made up of a first constituent being a 3- to 7-membered monocyclic fully saturated or partially unsaturated, non- aromatic heterocyclic ring B, which heterocyclic ring B comprises one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, and which heterocyclic ring B is optionally substituted by one or two oxo groups, and, optionally, fused to said first constituent, a second constituent being a benzene ring, a 3-7C-cycloalkane group, or an additional heterocyclic ring B as defined herein afore, whereby said Het ring or ring system is attached to the parent molecular group via a substitutable ring carbon or ring nitrogen atom.
• Het may include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, homopiperazinyl, morpholinyl or thiomorpholinyl, or tetrahydrofuranyl, and the partially unsaturated derivatives thereof such as e.g. pyrrolinyl, imidazolinyl or pyrazolinyl, and the oxo substituted derivatives of the aforementioned examples such as e.g.
• 2-oxopiperazinyl or 5-oxo-1 ,4-diazepanyl
• benzo-fused derivatives of the aforementioned examples such as e.g. indolinyl, isoindolinyl,
• Het radicals include those isomers of the abovementioned examples which are attached via a ring nitrogen atom, such as e.g., without being limited to, aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, homopiperidin-1-yl, piperazin-1-yl, homopiperazin-1-yl, morpholin-4-yl or thiomorpholin-4-yl.
• a ring nitrogen atom such as e.g., without being limited to, aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, homopiperidin-1-yl, piperazin-1-yl, homopiperazin-1-yl, morpholin-4-yl or thiomorpholin-4-yl.
• Het radicals include those isomers of the abovementioned examples which are attached via a ring carbon atom, such as e.g., without being limited to, pyrrolidin-2-yl, pyrrolidin-2-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl or piperazin-2-yl.
• Het radicals include those benzo-fused derivatives which are attached via the benzene ring to the parent molecular group, such as e.g. 1 ,3-benzodioxol-5-yl, 2,3-dihydro-1 ,4- benzodioxin-6-yl, 2,3-dihydrobenzothiophen-5-yl, 2,3-dihydrobenzothiophen-6-yl, chromen-6-yl, chromen-7-yl, chroman-6-yl, chroman-7-yl, 2,3-dihydrobenzofuran-5-yl, or 2,3-dihydrobenzofuran-6-yl.
• benzo-fused derivatives which are attached via the benzene ring to the parent molecular group, such as e.g. 1 ,3-benzodioxol-5-yl, 2,3-dihydro-1 ,4- benzodioxin-6-yl, 2,
• R2 is Het
• further more detailed exemplary Het radicals include morpholino (i.e. morpholin-4-yl).
• oxo forms a carbonyl moiety when attached at a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom.
• Mono- or di-(R201)-substituted imidazol-1-yl or pyrazol-1-yl stands for an imidazol-1-yl or pyrazol-1-yl radical, respectively, which is substituted by one or two radicals independently selected from R201 , such as mono- or di-methyl-substituted imidazol-1-yl or pyrazol-1-yl, respectively, like 2-methyl- imidazol-1-yl, 4-methyl-imidazol-1-yl or 5-methyl-imidazol-1-yl, or 2,4-dimethyl-imidazol-1-yl; in particular 2-methyl-imidazol-1-yl, 4-methyl-imidazol-1-yl or 2,4-dimethyl-imidazol-1-yl.
• R201- and/or R202-substituted pyridyl or pyrimidinyl, respectively may include, for example, methyl- substituted pyridyl or pyrimidinyl, respectively, like 4-methyl-pyridin-2-yl or 4-methyl-pyridin-3-yl.
• 1 N-(1-4C-alkyl)-imidazolyl or 1 N-(1-4C-alkyl)-pyrazolyl refers to imidazolyl or pyrazolyl, respectively, which is substituted by 1-4C-alkyl on the nitrogen atom in position 1 , such as e.g. 1 N- methyl-imidazolyl or 1 N-ethyl-imidazolyl, e.g. 1-methyl-imidazol-2-yl, 1-methyl-imidazol-5-yl or 1- ethyl-imidazol-2-yl; in particular 1-methyl-imidazol-2-yl or 1-methyl-imidazol-5-yl.
• R201 -substituted 1 N- (1-4C-alkyl)-imidazolyl or R201 -substituted 1 N-(1-4C-alkyl)-pyrazolyl, respectively may include, for example, methyl- or ethyl-substituted 1 N-(1-4C-alkyl)-imidazolyl or 1 N-(1-4C-alkyl)-pyrazolyl, respectively, like methyl-substituted 1 N-methyl-imidazolyl, e.g. 1 ,4-dimethyl-imidazol-2-yl or 1 ,5- dimethylimidazol-2-yl.
• 1 N-(H)-imidazolyl or 1 N-(H)-pyrazolyl refers to imidazolyl or pyrazolyl, respectively, which is substituted by hydrogen on the nitrogen atom in position 1 , such as e.g. 1 H-imidazol-2-yl or 1 H-imidazol-5-yl.
• R201 -substituted 1 N-(H)-imidazolyl or R101 -substituted 1 N-(H)-pyrazolyl, respectively may include, for example, methyl- or ethyl-substituted 1 N-(H)-imidazolyl or 1 N-(H)- pyrazolyl, respectively, like methyl-substituted 1 N-(H)-imidazolyl, e.g. 4-methyl-1 H-imidazol-2-yl or 5- methyl-1 H-imidazol-2-yl.
• (R2)-methyl or (R20)-methyl stand for methyl which is substituted by R2 or R20, respectively.
• the term 2-(R2)-ethyl or 2-(R20)-ethyl stands for ethyl which is substituted in 2-position by R2 or R20, respectively.
• the term 3-(R2)-propyl or 3-(R20)-propyl stands for propyl which is substituted in 3-position by R2 or R20, respectively.
• (Rba)-phenyl means that the phenyl radical is substituted by Rba, which is attached to any of the positions of the phenyl ring;
• 2-(Rba)-phenyl means that the phenyl radical is substituted by Rba, which is attached in the 2-position to the phenyl radical (i.e. the ortho position with respect to the binding position in which the phenyl ring is bonded to the parent molecular group).
• 5-(Rca)-furan-2-yl means that the furan-2-yl radical is substituted by Rca, which is attached in the 5-position to the furan-2-yl radical;
• the expression 5-(Rca)-4-(Rcb)-furan-2-yl means that the furan-2-yl radical is substituted by both Rca and Rcb, whereby the substituent Rca is bonded in the 5- position to the furan-2-yl radical, and the substituent Rcb is bonded in the 4-position to the furan-2-yl radical.
• radicals Har and Het include all the possible isomeric forms thereof, particularly the positional isomers thereof.
• pyridinyl or pyridyl includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl.
• phenyl radical may be substituted by its substituents or parent molecular groups at any possible position.
• heterocyclic groups alone or as part of other groups, mentioned herein may be substituted by their given substituents or parent molecular groups, unless otherwise noted, at any possible position, such as e.g. at any substitutable ring carbon or ring nitrogen atom.
• rings containing quaternizable imino-type ring nitrogen atoms may be preferably not quaternized on these imino-type ring nitrogen atoms by the mentioned substituents or parent molecular groups.
• any heteroatom of a heterocyclic ring with unsatisfied valences mentioned herein is assumed to have the hydrogen atom(s) to satisfy the valences.
• each definition is independent.
• Suitable salts for compounds of formula I according to this invention - depending on substitution - are all acid addition salts or all salts with bases. Particular mention may be made of the pharmacologically tolerable inorganic and organic acids and bases customarily used in pharmacy. Those suitable are, on the one hand, water-insoluble and, particularly, water-soluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulphosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulphonic acid, methanesulphonic acid or 3-hydroxy-2- naphthoic acid, the acids being employed
• salts with bases are - depending on substitution - also suitable.
• salts with bases are mentioned the lithium, sodium, potassium, calcium, aluminium, magnesium, titanium, ammonium, meglumine or guanidinium salts, here, too, the bases being employed in salt preparation in an equimolar quantitative ratio or one differing therefrom.
• Pharmacologically intolerable salts which can be obtained, for example, as process products during the preparation of the compounds according to this invention on an industrial scale, are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
• the compounds of formula I according to this invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of formula I according to this invention as well as all solvates and in particular all hydrates of the salts of the compounds of formula I according to this invention.
• hyperproliferation and analogous terms are used to describe aberrant / dysregulated cellular growth, a hallmark of diseases like cancer.
• This hyperproliferation might be caused by single or multiple cellular / molecular alterations in respective cells and can be, in context of a whole organism, of benign or malignant behaviour.
• Inhibition of cell proliferation and analogous terms is used herein to denote an ability of the compound to retard the growth of and/or kill a cell contacted with that compound as compared to cells not contacted with that compound. Most preferable this inhibition of cell proliferation is 100%, meaning that proliferation of all cells is stopped and/or cells undergo programmed cell death.
• the contacted cell is a neoplastic cell.
• a neoplastic cell is defined as a cell with aberrant cell proliferation.
• a benign neoplasia is described by hyperproliferation of cells, incapable of forming an aggressive, metastasizing tumor in- vivo.
• a malignant neoplasia is described by cells with different cellular and biochemical abnormalities, e.g. capable of forming tumor metastasis.
• the aquired functional abnormalities of malignant neoplastic cells are replicative potential ("hyperproliferation"), self-sufficiency in growth signals, insensitivity to anti-growth signals, evasion from apoptosis, sustained angiogenesis and tissue invasion and metastasis.
• Inducer of apoptosis and analogous terms are used herein to identify a compound which executes programmed cell death in cells contacted with that compound.
• Apoptosis is defined by complex biochemical events within the contacted cell, such as the activation of cystein specific proteinases ("caspases") and the fragmentation of chromatin.
• caspases cystein specific proteinases
• Induction of apoptosis in cells contacted with the compound might not necessarily be coupled with inhibition of cell proliferation.
• the inhibition of cell proliferation and/or induction of apoptosis is specific to cells with aberrant cell growth (hyperproliferation).
• cytotoxic is used in a more general sense to identify compounds which kill cells by various mechanisms, including the induction of apoptosis / programmed cell death in a cell cycle dependent or cell-cycle independent manner.
• Cell cycle specific and analogous terms are used herein to identify a compound as inducing apoptosis only in continously proliferating cells actively passing a specific phase of the cell cycle, but not in resting, non-dividing cells.
• Continously proliferating cells are typical for diseases like cancer and characterized by cells in all phases of the cell division cycle, namely in the G (“gap”) 1 , S (“DNA synthesis”), G2 and M (“mitosis”) phase.
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, or 1-7C-alkyl substituted by one or two substituents independently selected from
• Rb is -T-Q, in which
• T is 1-6C-alkylene or 3-7C-cycloalkylene, and either
• Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl, or
• Q is optionally substituted by Rca and/or Rcb, and is Har, or Q is attached via a carbon atom of the benzene ring to the parent molecular group, and is 1 ,3- benzodioxolyl, 2,3-dihydro-1 ,4-benzodioxinyl, chromenyl, chromanyl, 2,2-difluoro-1 ,3- benzodioxolyl, or 2,3-dihydrobenzofuranyl, or Q is attached via a carbon atom of the benzene ring to the parent molecular group, and is benzofuranyl, or
• Q is tetrahydrofuranyl, or Q is 3-7C-cycloalkyl
• each R2 may be the same or different and is independently selected from the group consisting of:
• each of said Har and Het is optionally substituted by one or two substituents independently selected from R10, in which each R3, R4, R5 and R6 may be the same or different and is each independently selected from the group consisting of: hydrogen, and 1-4C-alkyl, each R7 may be the same or different and is independently selected from the group consisting of: hydrogen, and 1-4C-alkyl, each R10 may be the same or different is independently selected from the group consisting of:
• each Rba, Rbb, Rbc, Rca and Rcb may be the same or different and is each independently selected from the group consisting of: 1-4C-alkyl, halogen, trifluoromethyl, cyano, 1-4C-alkoxycarbonyl, carboxyl, and hydroxyl,
• each Har is the same or different and is independently either a 5-membered monocyclic heteroaryl radical comprising one to four heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g. any one selected from furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, thiadiazolyl and oxadiazolyl, whereby said Har radical is attached to the parent molecular group via a ring carbon or ring nitrogen atom, or a 6-membered monocyclic heteroaryl radical comprising one or two nitrogen atoms, such as e.g. any one selected from pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl, whereby said Har radical is attached to the parent molecular group via a ring carbon atom,
• Het is a 3- to 7-membered monocyclic fully saturated heterocyclic ring comprising one or two heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g. any one selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, homopiperazinyl, morpholinyl and thiomorpholinyl, whereby said Het radical is attached to the parent molecular group via a ring carbon or ring nitrogen atom;
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, 1-4C-alkyl substituted by one substituent selected from R2, or 3-4C-alkyl substituted by two hydroxyl radicals on different carbon atoms, and either
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, or Q is optionally substituted by Rca and/or Rcb, and is pyridinyl, furanyl, thiophenyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl or imidazolyl, or Q is attached via a carbon atom of the benzene ring to the parent molecular group, and is 1 ,3- benzodioxolyl, 2,3-dihydro-1 ,4-benzodioxinyl, chromenyl, chromanyl, 2,2-difluoro-1 ,3- benzodioxolyl or 2,3-dihydrobenzofuranyl, or Q is attached via a carbon atom of the benzene ring to the parent molecular group, and is benzofuranyl, or
• Q is tetrahydrofuranyl, or Q is 3-7C-cycloalkyl
• each R2 may be the same or different and is independently selected from the group consisting of: Har, morpholino, 4-methyl-piperazin-1-yl, -C(O)R3, -C(O)OR4, -C(O)N(R5)R6,
• each of said Har and Het is optionally substituted by one or two substituents independently selected from R10, in which each R3, R4, R5 and R6 may be the same or different and is each independently selected from the group consisting of: hydrogen, and 1-4C-alkyl, R7 is hydrogen, either Har is bonded to the parent molecular group via a ring carbon atom or a ring nitrogen atom, and is imidazolyl, pyrazolyl or triazolyl, or Har is bonded to the parent molecular group via a ring carbon atom, and is pyridinyl, pyrazinyl or pyrimidinyl, R10 is 1-4C-alkyl
• each Rca and Rcb may be the same or different and is each independently selected from the group consisting of:
• Ra is -C(O)ORI , in which either
• R1 is 1-4C-alkyl such as e.g. methyl, ethyl or propyl, or
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is substituted by R2, in which R2 is pyridyl, pyrimidinyl, R201- and/or R202-substituted pyridyl, or R201- and/or R202-substituted pyrimidinyl, or
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is substituted by R2, in which R2 is 1 N-(1 -4C-alkyl)-imidazolyl, 1 N-(1 -4C-alkyl)-pyrazolyl, R201 -substituted 1 N-(1 -4C-alkyl)- imidazolyl, or R201 -substituted 1 N-(1-4C-alkyl)-pyrazolyl, or
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is substituted by R2, in which R2 is 1 N-(H)-imidazolyl, 1 N-(H)-pyrazolyl, R201 -substituted 1 N-(H)-imidazolyl, or R201 -substituted
• R1 is 3-4C-alkyl, such as e.g. propyl or butyl, which is substituted by two hydroxyl radicals on different carbon atoms, or R1 is 1-2C-alkyl, such as e.g. methyl or ethyl, which is substituted by 2,2-dimethyl-[1 ,3]dioxolan-4- yi, or
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is substituted by R2, in which
• R2 is -C(O)OR4, or
• R1 is 2-4C-alkyl, such as e.g. ethyl or propyl, which is substituted by R2, in which
• R2 is morpholino, -OC(O)R3, -OR4, phenyl-1-2C-alkoxy such as e.g. benzyloxy,
• 1-2C-alkoxy-2-3C-alkoxy such as e.g. 2-methoxyethoxy, or
• R1 is 2-4C-alkyl, such as e.g. ethyl or propyl, which is substituted by R2, in which R2 is imidazol-1-yl, pyrazol-1-yl, mono- or di-(R201)-substituted imidazol-1-yl, or mono- or di-
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, or
• Q is optionally substituted by Rca and/or Rcb, and is pyridinyl, furanyl, thiophenyl or pyrazol-1-yl, or
• Q is 1 ,3-benzodioxol-5-yl, 2,3-dihydro-1 ,4-benzodioxin-6-yl, 2,2-difluoro-1 ,3-benzodioxol-5-yl, chromen-6-yl, chromen-7-yl, chroman-6-yl, chroman-7-yl, 2,3-dihydrobenzofuran-5-yl, or 2,3- dihydrobenzofuran-6-yl, or Q is benzofuran-5-yl, or benzofuran-6-yl, or
• Q is tetrahydrofuranyl
• Q is 5-6C-cycloalkyl
• R201 is 1-4C-alkyl such as e.g. methyl or ethyl,
• R202 is 1-4C-alkyl such as e.g. methyl or ethyl
• each Rba and Rbb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl, fluorine, chlorine, bromine, and trifluoromethyl
• each Rca and Rcb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl, fluorine, chlorine, and trifluoromethyl;
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin- 2-yl or pyridin-3-yl,
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl,
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl,
• Rba is methyl, ethyl, chlorine or fluorine
• Rba is methyl, ethyl, chlorine or fluorine
• Q is 2-(Rca)-furan-3-yl, 5-(Rca)-furan-3-yl, or, especially, 5-(Rca)-furan-2-yl, in which
• Rca is methyl or chlorine
• Q is 5-(Rca)-3-(Rcb)-furan-2-yl, 2-(Rca)-4-(Rcb)-furan-3-yl, 2-(Rca)-5-(Rcb)-furan-3-yl, 2-(Rcb)-5- (Rca)-furan-3-yl, 5-(Rca)-4-(Rcb)-furan-3-yl, or, especially, 5-(Rca)-4-(Rcb)-furan-2-yl, in which Rca is methyl or chlorine, Rcb is methyl,
• Q is 2-(Rca)-thiophen-3-yl, 5-(Rca)-thiophen-3-yl, or, especially, 5-(Rca)-thiophen-2-yl, in which
• Rca is methyl or chlorine
• Q is 5-(Rca)-3-(Rcb)-thiophen-2-yl, 2-(Rca)-4-(Rcb)-thiophen -3-yl, 2-(Rca)-5-(Rcb)-thiophen-3-yl,
• Q is unsubstituted, and is pyridin-2-yl or pyridin-3-yl,
• R1 is methyl, ethyl or propyl, or
• R1 is (R2)-methyl, 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is pyridyl, pyrimidinyl, or methyl-substituted pyridyl, or
• R1 is 2,3-dihydroxy-propyl, or
• R1 is (R2)-methyl, 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is carboxyl or methoxycarbonyl, or
• R1 is 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is hydroxyl, methylcarbonyloxy, methoxy, ethoxy, benzyloxy, or 2-methoxyethoxy, or
• R1 is 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is imidazol-1-yl, or mono- or di-methyl-substituted imidazol-1-yl
• Q is unsubstituted, and is phenyl, or
• Q is unsubstituted, and is pyridinyl, furanyl or thiophenyl, or
• Q is substituted by Rba and/or Rbb, and is phenyl, or
• Q is substituted by Rca and/or Rcb, and is pyridinyl, furanyl or thiophenyl, in which each Rba and Rbb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl, fluorine and chlorine, each Rca and Rcb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl and chlorine;
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin- 2-yl or pyridin-3-yl,
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl,
• Rba is methyl, ethyl, chlorine or fluorine
• Rba is methyl, ethyl, chlorine or fluorine
• Q is 5-(Rca)-furan-3-yl, or, especially, 5-(Rca)-furan-2-yl, in which
• Rca is methyl or chlorine
• Q is 5-(Rca)-4-(Rcb)-furan-3-yl, or, especially, 5-(Rca)-4-(Rcb)-furan-2-yl, in which
• Rca is methyl or chlorine
• Rcb is methyl
• Q is 5-(Rca)-thiophen-3-yl, or, especially, 5-(Rca)-thiophen-2-yl, in which
• Rca is methyl or chlorine
• Q is unsubstituted, and is pyridin-2-yl or pyridin-3-yl,
• subembodiment Q is unsubstituted, and is furan-2-yl
• Ra is -C(O)ORI , in which either
• R1 is methyl, ethyl or propyl, or
• R1 is (R2)-methyl, 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is pyridyl, pyrimidinyl, or methyl-substituted pyridyl, or
• R1 is (R2)-methyl, 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is 1 N-methyl-imidazolyl
• R1 is 2,3-dihydroxy-propyl, or
• R1 is (R2)-methyl, 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is carboxyl or methoxycarbonyl, or
• R1 is 2-(R2)-ethyl, or 3-(R2)-propyl, in which R2 is hydroxyl, methylcarbonyloxy, methoxy, ethoxy, benzyloxy, or 2-methoxyethoxy, or
• R1 is 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is imidazol-1-yl, or mono- or di-methyl-substituted imidazol-1-yl
• Q is unsubstituted, and is phenyl, or
• Q is unsubstituted, and is pyridinyl, furanyl or thiophenyl, or
• Q is substituted by Rba and/or Rbb, and is phenyl, or
• Q is substituted by Rca and/or Rcb, and is pyridinyl, furanyl or thiophenyl, in which each Rba and Rbb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl, fluorine and chlorine, each Rca and Rcb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl and chlorine;
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin- 2-yl or pyridin-3-yl,
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl,
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl,
• Rba is methyl, ethyl, chlorine or fluorine
• Rba is methyl, ethyl, chlorine or fluorine, in another particular subembodiment
• Q is 5-(Rca)-furan-3-yl, or, especially, 5-(Rca)-furan-2-yl, in which
• Rca is methyl or chlorine
• Q is 5-(Rca)-4-(Rcb)-furan-3-yl, or, especially, 5-(Rca)-4-(Rcb)-furan-2-yl, in which
• Rca is methyl or chlorine
• Rcb is methyl
• Q is 5-(Rca)-thiophen-3-yl, or, especially, 5-(Rca)-thiophen-2-yl, in which
• Rca is methyl or chlorine
• Q is unsubstituted, and is pyridin-2-yl or pyridin-3-yl,
• subembodiment Q is unsubstituted, and is furan-2-yl
• Ra is -C(O)ORI , in which either
• R1 is (R2)-methyl, or 2-(R2)-ethyl, in which
• R2 is pyridyl
• R1 is 2,3-dihydroxy-propyl, or
• R1 is 2-(R2)-ethyl, in which
• R2 is hydroxyl or methoxy
• R1 is 2-(R2)-ethyl, in which
• R2 is imidazol-1-yl
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin-
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl, or
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl, or
• Q is 2-(Rba)-phenyl, in which Rba is methyl, ethyl, chlorine or fluorine, or
• Q is 3-(Rba)-phenyl, in which Rba is methyl, ethyl, chlorine or fluorine, or Q is 5-(Rca)-furan-2-yl, in which Rca is methyl or chlorine, or
• Rca is methyl or chlorine
• Rcb is methyl
• Rca is methyl or chlorine
• Q is unsubstituted, and is pyridin-2-yl
• Q is unsubstituted, and is thiophen-2-yl
• Q is unsubstituted, and is pyridin-2-yl
• Ra is -C(O)ORI , in which either
• R1 is (R2)-methyl,or 2-(R2)-ethyl, in which
• R2 is pyridyl
• R1 is 2,3-dihydroxy-propyl, or
• R1 is 2-(R2)-ethyl, in which
• R2 is hydroxyl
• R1 is 2-(R2)-ethyl, in which
• R2 is imidazol-1-yl
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin-
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl, or
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl, or
• Q is 2-(Rba)-phenyl, in which Rba is methyl, ethyl, chlorine or fluorine, or
• Q is 3-(Rba)-phenyl, in which Rba is methyl, ethyl, chlorine or fluorine, or
• Q is 5-(Rca)-furan-2-yl, in which Rca is methyl or chlorine, or
• Q is unsubstituted, and is pyridin-2-yl
• Q is unsubstituted, and is thiophen-2-yl
• Q is unsubstituted, and is pyridin-2-yl
• subembodiment Q is unsubstituted, and is furan-2-yl; and the salts thereof.
• Ra is -C(O)ORI , in which
• R1 is 2-7C-alkyl substituted by R20, Rb is -T-Q, in which
• T is 1-6C-alkylene or S-TC-cycloalkylene, and either
• Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl, or
• Q is optionally substituted by Rca and/or Rcb, and is Har, or
• Q is tetrahydrofuranyl
• Q is attached via a carbon atom of the benzene ring to the parent molecular group, and is 1 ,3- benzodioxolyl, 2,3-dihydro-1 ,4-benzodioxinyl, chromenyl, chromanyl, 2,2-difluoro-1 ,3- benzodioxolyl, or 2,3-dihydrobenzofuranyl, or
• Q is 3-7C-cycloalkyl, wherein R20 is selected from guanidino, hydroxy-2-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, pyridyl-1-4C-alkoxy, (1-4C-alkoxy-2-
• each Rba, Rbb, Rbc, Rca and Rcb may be the same or different and is each independently selected from the group consisting of:
• each Har is the same or different and is independently either a 5-membered monocyclic heteroaryl radical comprising one to four heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g.
• Har radical is attached to the parent molecular group via a ring carbon or ring nitrogen atom, or a 6-membered monocyclic heteroaryl radical comprising one or two nitrogen atoms, such as e.g. any one selected from pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl, whereby said Har radical is attached to the parent molecular group via a ring carbon atom;
• Ra is -C(O)ORI , in which
• R1 is 2-4C-alkyl substituted by R20, and either
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, or
• Q is optionally substituted by Rca and/or Rcb, and is pyridinyl, furanyl, thiophenyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl or imidazolyl, or
• Q is tetrahydrofuranyl, or Q is attached via a carbon atom of the benzene ring to the parent molecular group, and is 1 ,3- benzodioxolyl, 2,3-dihydro-1 ,4-benzodioxinyl, chromenyl, chromanyl, 2,2-difluoro-1 ,3- benzodioxolyl, or 2,3-dihydrobenzofuranyl, or
• Q is 3-7C-cycloalkyl, wherein R20 is selected from hydroxy-2-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, pyridyl-1-4C-alkoxy, (1-4C-alkoxy-2-4C-alkoxy)-
• each Rba and Rbb may be the same or different and is each independently selected from the group consisting of:
• each Rca and Rcb may be the same or different and is each independently selected from the group consisting of:
• Ra is -C(O)ORI , in which
• R1 is 2-4C-alkyl, such as e.g. ethyl or propyl, which is substituted by R20, and either
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, or Q is optionally substituted by Rca and/or Rcb, and is pyridinyl, furanyl, thiophenyl or pyrazol-1-yl, or
• Q is tetrahydrofuranyl
• Q is 1 ,3-benzodioxol-5-yl, 2,3-dihydro-1 ,4-benzodioxin-6-yl, 2,2-difluoro-1 ,3-benzodioxol-5-yl, chromen-6-yl, chromen-7-yl, chroman-6-yl, chroman-7-yl, 2,3-dihydrobenzofuran-5-yl, or 2,3- dihydrobenzofuran-6-yl, or
• Q is 5-6C-cycloalkyl, wherein R20 is selected from
• each Rba and Rbb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl, fluorine, chlorine, bromine, and trifluoromethyl, Rca is methyl, Rcb is methyl;
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin- 2-yl or pyridin-3-yl,
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl,
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl,
• Rba is methyl, ethyl, chlorine or fluorine
• Rba is methyl, ethyl, chlorine or fluorine
• Q is 2-(Rca)-furan-3-yl, 5-(Rca)-furan-3-yl, or, especially, 5-(Rca)-furan-2-yl, in which
• Rca is methyl, in another particular subembodiment
• Q is 5-(Rca)-3-(Rcb)-furan-2-yl, 2-(Rca)-4-(Rcb)-furan-3-yl, 2-(Rca)-5-(Rcb)-furan-3-yl, 2-(Rcb)-5- (Rca)-furan-3-yl, 5-(Rca)-4-(Rcb)-furan-3-yl, or, especially, 5-(Rca)-4-(Rcb)-furan-2-yl, in which Rca is methyl, Rcb is methyl,
• Q is 2-(Rca)-thiophen-3-yl, 5-(Rca)-thiophen-3-yl, or, especially, 5-(Rca)-thiophen-2-yl, in which
• Rca is methyl
• Q is 5-(Rca)-3-(Rcb)-thiophen-2-yl, 2-(Rca)-4-(Rcb)-thiophen -3-yl, 2-(Rca)-5-(Rcb)-thiophen-3-yl,
• Q is unsubstituted, and is pyridin-2-yl or pyridin-3-yl,
• Ra is -C(O)ORI , in which R1 is 2-(R20)-ethyl, or 3-(R20)-propyl, in which
• R20 is 2-methoxyethoxy; and wherein either
• Q is unsubstituted, and is phenyl, or
• Q is substituted by Rba and/or Rbb, and is phenyl, or
• Q is unsubstituted, and is pyridinyl, furanyl, or thiophenyl, or
• Q is substituted by Rca and/or Rcb, and is furanyl, thiophenyl or pyrazol-1-yl, or
• Q is tetrahydrofuranyl
• Q is 1 ,3-benzodioxol-5-yl, 2,3-dihydro-1 ,4-benzodioxin-6-yl, or 2,2-difluoro-1 ,3-benzodioxol-5-yl, or
• Q is cyclohexyl, in which each Rba and Rbb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl, chlorine, bromine, and fluorine, Rca is methyl, Rcb is methyl;
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin- 2-yl or pyridin-3-yl,
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl,
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl,
• Rba is methyl, ethyl, chlorine or fluorine
• Q is unsubstituted, and is pyridin-2-yl or pyridin-3-yl,
• subembodiment Q is unsubstituted, and is furan-2-yl
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, or 1-7C-alkyl substituted by one or two substituents independently selected from R2, Rb is -T-Q, in which
• T is 1-6C-alkylene or 3-7C-cycloalkylene, and either
• Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl, or
• Q is optionally substituted by Rca and/or Rcb, and is Har, or
• Q is optionally substituted by Rda, and is Het, or
• R2 is 3-7C-cycloalkyl, wherein each R2 may be the same or different and is independently selected from the group consisting of:
• each R3, R4, R5 and R6 may be the same or different and is each independently selected from the group consisting of: hydrogen, and 1-4C-alkyl
• each R7 may be the same or different and is independently selected from the group consisting of: hydrogen, and 1-4C-alkyl
• each R10 may be the same or different is independently selected from the group consisting of:
• each Rba, Rbb, Rbc, Rca, Rcb and Rda may be the same or different and is each independently selected from the group consisting of:
• each Har is the same or different and is independently either a 5-membered monocyclic heteroaryl radical comprising one to four heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g.
• Har radical is attached to the parent molecular group via a ring carbon or ring nitrogen atom, or a 6-membered monocyclic heteroaryl radical comprising one or two nitrogen atoms, such as e.g. any one selected from pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl, whereby said Har radical is attached to the parent molecular group via a ring carbon atom,
• each Het is the same or different and is independently a 3- to 7-membered monocyclic fully saturated heterocyclic ring comprising one or two heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g. any one selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, homopiperazinyl, morpholinyl and thiomorpholinyl, whereby said Het radical is attached to the parent molecular group via a ring carbon or ring nitrogen atom;
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, or 1-7C-alkyl substituted by one or two substituents independently selected from
• Rb is -T-Q, in which
• T is 1-6C-alkylene or 3-7C-cycloalkylene, and either
• Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl, or Q is optionally substituted by Rca and/or Rcb, and is Har, or
• Q is tetrahydrofuranyl
• Q is attached via a carbon atom of the benzene ring to the parent molecular group, and is 1 ,3- benzodioxolyl, 2,3-dihydro-1 ,4-benzodioxinyl, chromenyl, chromanyl, 2,2-difluoro-1 ,3- benzodioxolyl, or 2,3-dihydrobenzofuranyl, or
• R2 is 3-7C-cycloalkyl, wherein each R2 may be the same or different and is independently selected from the group consisting of:
• each of said Har and Het is optionally substituted by one or two substituents independently selected from R10, in which each R3, R4, R5 and R6 may be the same or different and is each independently selected from the group consisting of: hydrogen, and 1-4C-alkyl, each R7 may be the same or different and is independently selected from the group consisting of: hydrogen, and 1-4C-alkyl, each R10 may be the same or different is independently selected from the group consisting of:
• each Rba, Rbb, Rbc, Rca and Rcb may be the same or different and is each independently selected from the group consisting of:
• each Har is the same or different and is independently either a 5-membered monocyclic heteroaryl radical comprising one to four heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g.
• Har radical is attached to the parent molecular group via a ring carbon or ring nitrogen atom, or a 6-membered monocyclic heteroaryl radical comprising one or two nitrogen atoms, such as e.g.
• each Het is the same or different and is independently a 3- to 7-membered monocyclic fully saturated heterocyclic ring comprising one or two heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g.
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, or 1-4C-alkyl substituted by one or two substituents independently selected from
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, or Q is optionally substituted by Rca and/or Rcb, and is pyridinyl, furanyl, thiophenyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl or imidazolyl, or
• Q is tetrahydrofuranyl
• Q is 3-7C-cycloalkyl, wherein each R2 may be the same or different and is independently selected from the group consisting of: pyridinyl, morpholino,
• each R3, R4, R5 and R6 may be the same or different and is each independently selected from the group consisting of: hydrogen, and 1-4C-alkyl, R7 is hydrogen, each Rba and Rbb may be the same or different and is each independently selected from the group consisting of:
• each Rca and Rcb may be the same or different and is each independently selected from the group consisting of:
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, 1-4C-alkyl substituted by one substituent selected from R2, or 3-4C-alkyl substituted by two hydroxyl radicals on different carbon atoms, and either
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, or Q is optionally substituted by Rca and/or Rcb, and is pyridinyl, furanyl, thiophenyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl or imidazolyl, or
• Q is tetrahydrofuranyl, or Q is attached via a carbon atom of the benzene ring to the parent molecular group, and is 1 ,3- benzodioxolyl, 2,3-dihydro-1 ,4-benzodioxinyl, chromenyl, chromanyl, 2,2-difluoro-1 ,3- benzodioxolyl, or 2,3-dihydrobenzofuranyl, or
• Q is 3-7C-cycloalkyl, wherein each R2 may be the same or different and is independently selected from the group consisting of: pyridinyl, pyrimidinyl, pyrazinyl, triazol-1-yl, imidazol-1-yl, pyrazol-1-yl, morpholino, 1 N-(1-4C- alkyl)-imidazolyl, 1 N-(1-4C-alkyl)-pyrazolyl, 2,2-dimethyl-[1 ,3]dioxolan-4-yl,
• each R3, R4, R5 and R6 may be the same or different and is each independently selected from the group consisting of: hydrogen, and 1-4C-alkyl, R7 is hydrogen, each Rba and Rbb may be the same or different and is each independently selected from the group consisting of:
• each Rca and Rcb may be the same or different and is each independently selected from the group consisting of:
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, such as e.g. ethyl, or
• 1-4C-alkyl such as e.g. ethyl or propyl, which is substituted by one or two substituents independently selected from R2, and either
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, or
• Q is optionally substituted by Rca and/or Rcb, and is pyridinyl, furanyl, thiophenyl or pyrazol-1-yl, or
• Q is tetrahydrofuranyl, or Q is 5-6C-cycloalkyl, wherein each R2 may be the same or different and is independently selected from the group consisting of: pyridinyl, morpholino,
• each R4 may be the same or different and is independently selected from the group consisting of: hydrogen, and 1-4C-alkyl
• each Rba and Rbb may be the same or different and is each independently selected from the group consisting of: methyl, fluorine, chlorine, and trifluoromethyl, Rca is methyl, Rcb is methyl;
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin- 2-yl or pyridin-3-yl,
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl,
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl,
• Q is 2-(Rca)-furan-3-yl, 5-(Rca)-furan-3-yl, or, especially, 5-(Rca)-furan-2-yl, in which
• Rca is methyl
• Q is 5-(Rca)-3-(Rcb)-furan-2-yl, 2-(Rca)-4-(Rcb)-furan-3-yl, 2-(Rca)-5-(Rcb)-furan-3-yl, 2-(Rcb)-5- (Rca)-furan-3-yl, 5-(Rca)-4-(Rcb)-furan-3-yl, or, especially, 5-(Rca)-4-(Rcb)-furan-2-yl, in which Rca is methyl, Rcb is methyl,
• Q is 2-(Rca)-thiophen-3-yl, 5-(Rca)-thiophen-3-yl, or, especially, 5-(Rca)-thiophen-2-yl, in which
• Rca is methyl
• Q is 5-(Rca)-3-(Rcb)-thiophen-2-yl, 2-(Rca)-4-(Rcb)-thiophen -3-yl, 2-(Rca)-5-(Rcb)-thiophen-3-yl,
• Q is unsubstituted, and is pyridin-2-yl or pyridin-3-yl,
• Ra is -C(O)ORI , in which R1 is 1-4C-alkyl such as e.g. methyl, ethyl or propyl, or pyridyl-1 -4C-alkyl such as e.g. pyridylmethyl, 2-pyridylethyl or 3-pyridylpropyl, or
• 2-4C-alkyl such as e.g. ethyl or propyl, which is substituted by one substituent selected from
• 3-4C-alkyl such as e.g. propyl or butyl, which is substituted by two hydroxyl radicals on different carbon atoms, and either
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, or
• Q is optionally substituted by Rca and/or Rcb, and is pyridinyl, furanyl, thiophenyl or pyrazol-1-yl, or
• Q is tetrahydrofuranyl, or Q is 1 ,3-benzodioxol-5-yl, 2,3-dihydro-1 ,4-benzodioxin-6-yl, 2,2-difluoro-1 ,3-benzodioxol-5-yl, chromen-6-yl, chromen-7-yl, chroman-6-yl, chroman-7-yl, 2,3-dihydrobenzofuran-5-yl, or 2,3- dihydrobenzofuran-6-yl, or
• Q is 5-6C-cycloalkyl, wherein each R2 may be the same or different and is independently selected from the group consisting of: morpholino,
• R3 is 1-4C-alkyl such as e.g. methyl
• each R4 may be the same or different and is independently selected from the group consisting of: hydrogen, and 1-4C-alkyl such as e.g. methyl or ethyl
• each Rba and Rbb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl, fluorine, chlorine, bromine, and trifluoromethyl
• Rca is methyl
• Rcb is methyl
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin- 2-yl or pyridin-3-yl, in another particular subembodiment
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl,
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl,
• Rba is methyl, ethyl, chlorine or fluorine
• Rba is methyl, ethyl, chlorine or fluorine
• Q is 2-(Rca)-furan-3-yl, 5-(Rca)-furan-3-yl, or, especially, 5-(Rca)-furan-2-yl, in which
• Rca is methyl
• Q is 5-(Rca)-3-(Rcb)-furan-2-yl, 2-(Rca)-4-(Rcb)-furan-3-yl, 2-(Rca)-5-(Rcb)-furan-3-yl, 2-(Rcb)-5- (Rca)-furan-3-yl, 5-(Rca)-4-(Rcb)-furan-3-yl, or, especially, 5-(Rca)-4-(Rcb)-furan-2-yl, in which Rca is methyl, Rcb is methyl,
• Q is 2-(Rca)-thiophen-3-yl, 5-(Rca)-thiophen-3-yl, or, especially, 5-(Rca)-thiophen-2-yl, in which
• Rca is methyl
• Q is 5-(Rca)-3-(Rcb)-thiophen-2-yl, 2-(Rca)-4-(Rcb)-thiophen -3-yl, 2-(Rca)-5-(Rcb)-thiophen-3-yl,
• Q is unsubstituted, and is pyridin-2-yl or pyridin-3-yl,
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, such as e.g. ethyl, and either
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, or
• Q is optionally substituted by Rca and/or Rcb, and is furanyl, thiophenyl or pyrazol-1-yl, or
• Q is pyridinyl
• Q is tetrahydrofuranyl
• Q is cyclohexyl, wherein each Rba and Rbb may be the same or different and is each independently selected from the group consisting of: methyl, chlorine, and fluorine, Rca is methyl, Rcb is methyl; in a particular subembodiment
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin- 2-yl or pyridin-3-yl,
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl,
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl,
• Q is unsubstituted, and is pyridin-2-yl
• Ra is -C(O)ORI , in which either
• R1 is methyl, ethyl or propyl, or
• R1 is pyridylmethyl, 2-pyridylethyl or 3-pyridylpropyl, or
• R2 is hydroxyl, methoxycarbonyl, methylcarbonyloxy, methoxy, ethoxy or benzyloxy; and wherein either
• Q is unsubstituted, and is phenyl, or
• Q is substituted by Rba and/or Rbb, and is phenyl, or
• Q is unsubstituted, and is pyridinyl, furanyl, or thiophenyl, or
• Q is substituted by Rca and/or Rcb, and is furanyl, thiophenyl or pyrazol-1-yl, or
• Q is tetrahydrofuranyl
• Q is 1 ,3-benzodioxol-5-yl, 2,3-dihydro-1 ,4-benzodioxin-6-yl, or 2,2-difluoro-1 ,3-benzodioxol-5-yl, or
• Q is cyclohexyl, in which each Rba and Rbb may be the same or different and is each independently selected from the group consisting of: methyl, ethyl, chlorine, bromine, and fluorine, Rca is methyl, Rcb is methyl;
• Q is unsubstituted, and is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, especially pyridin- 2-yl or pyridin-3-yl,
• Q is unsubstituted, and is furanyl, e.g. furan-2-yl or furan-3-yl, especially furan-2-yl,
• Q is unsubstituted, and is thiophenyl, e.g. thiophen-2-yl or thiophen-3-yl, especially thiophen-2-yl,
• Rba is methyl, ethyl, chlorine or fluorine
• Rba is methyl, ethyl, chlorine or fluorine
• Q is unsubstituted, and is pyridin-2-yl or pyridin-3-yl,
• subembodiment Q is unsubstituted, and is furan-2-yl
• a first embodimental detail (detail a) of the compounds of formula I according to this invention includes those compounds of formula I, in which
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, particularly ethyl.
• a second embodimental detail (detail b) of the compounds of formula I according to this invention includes those compounds of formula I, in which
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which
• R2 has one of the meanings as defined in the compounds mentioned above.
• a subdetail (detail b1) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-4C-alkoxy, hydroxyl, 1-4C-alkoxycarbonyl, carboxyl, ureido, mono- or di-1-4C- alkylaminocarbonyl, carbamoyl, 1-4C-alkylcarbonylamino, mono- or di-1-4C-alkylamino, amino,
• Har has one of the meanings as defined in the compounds mentioned above, Het has one of the meanings as defined in the compounds mentioned above.
• Another subdetail (detail b1 ') of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, (1-4C-alkoxy-2-4C-alkoxy)-2-4C-alkoxy, hydroxyl, 1- 4C-alkoxycarbonyl, phenyl-1-4C-alkoxy, 1-4C-alkylcarbonyloxy, carboxyl, mono- or di-1-4C- alkylaminocarbonyl, carbamoyl, 1-4C-alkylcarbonylamino, or Har, in which
• Har has one of the meanings as defined in the compounds mentioned above.
• a further subdetail (detail b2) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-4C-alkoxy, hydroxyl, 1-4C-alkoxycarbonyl, carboxyl, ureido, mono- or di-1-4C- alkylaminocarbonyl, carbamoyl, 1-4C-alkylcarbonylamino, mono- or di-1-4C-alkylamino, or amino.
• Another subdetail (detail b2') of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which R2 is 1-4C-alkoxy, hydroxyl, phenyl-1-4C-alkoxy, 1-4C-alkylcarbonyloxy, or 1-4C- alkylcarbonylamino.
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is substituted by R2, in which
• R2 is 1-4C-alkoxycarbonyl, carboxyl, mono- or di-1-4C-alkylaminocarbonyl, or carbamoyl.
• a further subdetail (detail b3) of the compounds according to detail b of this invention includes those compounds of formula I, in which either
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-4C-alkoxy, hydroxyl, phenyl-1-4C-alkoxy, or 1-4C-alkylcarbonyloxy, or
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-4C-alkoxycarbonyl, or carboxyl.
• Another subdetail (detail b3') of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-4C-alkoxy-2-4C-alkoxy, or (1-4C-alkoxy-2-4C-alkoxy)-2-4C-alkoxy.
• a further subdetail (detail b4) of the compounds according to detail b of this invention includes those compounds of formula I, in which either
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-2C-alkoxy, hydroxyl, or 1-2C-alkylcarbonyloxy, or
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-2C-alkoxycarbonyl, or carboxyl.
• Another subdetail (detail b4') of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-2C-alkoxy-ethoxy, or (1-2C-alkoxy-ethoxy)-ethoxy.
• a further subdetail (detail b5) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is Har, in which
• Har is optionally substituted by one or two substituents independently selected from R10 as defined in the compounds mentioned above, and is a 5-membered monocyclic heteroaryl radical comprising one to four heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g. any one selected from furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, thiadiazolyl and oxadiazolyl, whereby said Har radical is attached to the adjacent 1-4C-alkyl radical via a ring carbon or ring nitrogen atom.
• a further subdetail (detail b6) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which
• R2 is Har, in which
• Har is optionally substituted by one or two substituents independently selected from R10 as defined in the compounds mentioned above, and is a 6-membered monocyclic heteroaryl radical comprising one or two nitrogen atoms, such as e.g. any one selected from pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl, whereby said Har radical is attached to the adjacent 1-4C-alkyl radical via a ring carbon atom.
• a further subdetail (detail b7) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is Het, in which
• Het is optionally substituted by one substituent selected from R10 as defined in the compounds mentioned above, and is a 3- to 7-membered monocyclic fully saturated heterocyclic ring comprising one or two heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g. any one selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, homopiperazinyl, morpholinyl and thiomorpholinyl, whereby said Het radical is attached to the adjacent 1-4C-alkyl radical via a ring carbon or ring nitrogen atom.
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is morpholino
• a further subdetail (detail b8) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which R2 is Har, in which
• Har is optionally substituted by one or two substituents independently selected from R10 as defined in the compounds mentioned above, and is pyridinyl.
• a further subdetail (detail b9) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is Har, in which
• Har is optionally mono-substituted by R10, and is pyridinyl, imidazolyl (e.g. imidazol-1-yl) or pyrazolyl (e.g. pyrazol-1-yl), in which R10 is 1-4C-alkyl, such as e.g. Har is pyridinyl, imidazol-1-yl, pyrazol-1-yl, 1 N-(methyl)-imidazolyl or 1 N-(methyl)-pyrazolyl.
• a further subdetail (detail b10) of the compounds according to detail b of this invention includes those compounds of formula I, in which R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which
• R2 is Har, in which
• Har is unsubstituted, and is pyridinyl.
• a further subdetail (detail b11) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is Het, in which
• Het is unsubstituted, and is morpholino or piperazino, or 4-methyl-piperazino.
• a further subdetail (detail b12) of the compounds according to detail b of this invention include those compounds of formula I, in which either
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-4C-alkoxy, such as e.g. methoxy or ethoxy, or hydroxyl, or
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-4C-alkoxycarbonyl, such as e.g. methoxycarbonyl, or carboxyl.
• a further subdetail (detail b13) of the compounds according to detail b of this invention include those compounds of formula I, in which either
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is methoxy, ethoxy, hydroxyl, 2-methoxyethoxy or methylcarbonyloxy, or
• R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is mono-substituted by R2, in which
• R2 is methoxycarbonyl
• a further subdetail (detail b14) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is 1-4C-alkoxy, such as e.g. methoxy or ethoxy, or hydroxyl.
• Another subdetail (detail b14') of the compounds according to detail b of this invention include those compounds of formula I, in which R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which R2 is 2-methoxyethoxy.
• a further subdetail (detail b15) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is methoxy, hydroxyl, methoxycarbonyl, methylcarbonyloxy, or 2-methoxyethoxy.
• Another subdetail (detail b15') of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 2-(R2)-ethyl, or 3-(R2)-propyl, in which
• R2 is methoxy, ethoxy, hydroxyl, methylcarbonyloxy, or 2-methoxyethoxy.
• a further subdetail (detail b16) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 2-(R2)-ethyl, in which
• R2 is methoxy, hydroxyl, or 2-methoxyethoxy.
• a further subdetail (detail b17) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is propyl or butyl, each of which is bisubstituted by hydroxyl on different carbon atoms, such as e.g. 2,3-dihydroxy-propyl.
• a further subdetail (detail b18) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is 2,3-dihydroxypropyl.
• a further subdetail (detail b19) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is 2-methoxyethyl.
• a further subdetail (detail b20) of the compounds according to detail b of this invention include those compounds of formula I, in which R1 is 2-hydroxyethyl.
• a further subdetail (detail b21) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is pyridylmethyl, 2-pyridylethyl or 3-pyridylpropyl, such as e.g. pyridin-2-yl-methyl, pyridin-3-yl- methyl, pyridin-4-yl-methyl, 2-(py rid in-2-y I )-ethyl , 2-(pyrid in-3-yl )-ethy I or 2-(py rid in-4-y I )-ethy I .
• a further subdetail (detail b22) of the compounds according to detail b of this invention includes those compounds of formula I, in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is mono-substituted by R2, in which
• R2 is Har or Het, in which
• Har is unsubstituted, and is pyridinyl
• Het is unsubstituted, and is morpholino.
• a further subdetail (detail b23) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is pyridylmethyl, such as e.g. pyridin-2-yl-methyl, pyridin-3-yl-methyl or pyridin-4-yl-methyl.
• a further subdetail (detail b24) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is 2-pyridylethyl, such as e.g. 2-(py rid in-2-y I )-ethyl , 2-(pyrid in-3-yl )-ethy I or 2-(py rid in-4-y I )-ethy I .
• a further subdetail (detail b25) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is (R2)-methyl, 2-(R2)-ethyl or 3-(R2)-propyl, in which
• R2 is R201- and/or R202-substituted pyridyl, in which
• R201 is methyl
• R202 is methyl
• a further subdetail (detail b26) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is 2-(R2)-ethyl or 3-(R2)-propyl, in which
• R2 is imidazol-1-yl.
• a further subdetail (detail b27) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is 2-(R2)-ethyl or 3-(R2)-propyl, in which
• R2 is mono- or di-methyl-substituted imidazol-1-yl.
• a further subdetail (detail b28) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is (R2)-methyl, 2-(R2)-ethyl or 3-(R2)-propyl, in which
• R2 is 1 N-methyl-imidazolyl.
• a further subdetail (detail b29) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is 2-(R2)-ethyl, in which
• R2 is mono- or di-methyl-substituted imidazol-1-yl, such as e.g. 2-methyl-imidazol-1-yl, 4-methyl- imidazol-1-yl or 2,4-dimethyl-imidazol-1-yl.
• a further subdetail (detail b30) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is (R2)-methyl or 2-(R2)-ethyl, in which
• R2 is 1 N-methyl-imidazolyl, such as e.g. 1-methyl-imidazol-2-yl or 1-methyl-imidazol-5-yl.
• a further subdetail (detail b31) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is (1-methyl-imidazol-2-yl)-methyl or (1-methyl-imidazol-5-yl)-methyl.
• a further subdetail (detail b32) of the compounds according to detail b of this invention include those compounds of formula I, in which
• R1 is 2-(imidazol-1-yl)-ethyl.
• a third embodimental detail (detail c) of the compounds of formula I according to this invention includes those compounds of formula I, in which
• Ra is -C(O)ORI , in which R1 is 1-4C-alkyl, such as e.g. methyl, ethyl or propyl, which is substituted by one or two substituents independently selected from R2 as defined in the compounds mentioned above.
• a subdetail (detail d) of the compounds according to detail c of this invention includes those compounds of formula I, in which
• Ra is -C(O)ORI , in which
• R1 is 1-4C-alkyl, such as e.g. ethyl or propyl, which is substituted by one or two substituents independently selected from R2, wherein each R2 may be the same or different and is each independently selected from the group consisting of: 1-4C-alkoxy, hydroxyl, 1-4C-alkoxycarbonyl, carboxyl, mono- or di-1-4C-alkylaminocarbonyl, or carbamoyl.
• a first embodimental variant (variant a) of the compounds of formula I according to this invention includes those compounds of formula I, which are from formula Ia
• a second embodimental variant (variant b) of the compounds of formula I according to this invention includes those compounds of formula I, which are from formula Ib
• one subvariant of variant b includes compounds of formula Ib, in which the radicals -N(H)-C(O)- and Q are located at the opposite side of the plane defined by the cyclopropane ring.
• a third embodimental variant (variant c) of the compounds of formula I according to this invention includes those compounds of formula I, which are from formula Ic
• one subvariant of variant c includes compounds of formula Ic*, another subvariant of variant c includes compounds of formula Ic**
• a fourth embodimental variant (variant d) of the compounds of formula I according to this invention includes those compounds of formula I, which are from formulae Id or Id'
• a fourth embodimental variant (variant e) of the compounds of formula I according to this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl, in which
• Rba has one of the meanings as defined in the compounds mentioned above,
• Rbb has one of the meanings as defined in the compounds mentioned above,
• Rbc has one of the meanings as defined in the compounds mentioned above.
• a subvariant (variant e1) of the compounds according to variant e of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is optionally substituted by Rba and/or Rbb, and is phenyl, in which
• Rba is 1-4C-alkyl, halogen, trifluoromethyl, or hydroxyl
• Rbb is 1-4C-alkyl, halogen, trifluoromethyl, or hydroxyl.
• a further subvariant (variant e2) of the compounds according to variant e of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is optionally substituted by Rba, and is phenyl, in which
• Rba is methyl, ethyl, fluorine or chlorine; especially, methyl, fluorine or chlorine.
• a further subvariant (variant e3) of the compounds according to variant e of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is any one selected from the group consisting of phenyl, 2-chlorophenyl, 2-methylphenyl, 2- fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-fluorophenyl, 4-chlorophenyl, 4-methylphenyl and 4-fluorophenyl; especially, 2-chlorophenyl, 2-methylphenyl, 2-fluorophenyl, 3-chlorophenyl, 3-methylphenyl and 3-fluorophenyl.
• a further subvariant (variant e4) of the compounds according to variant e of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is optionally substituted by Rba, and is phenyl, in which
• Rba is methyl, fluorine, bromine, or chlorine.
• a further subvariant (variant e5) of the compounds according to variant e of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is any one selected from the group consisting of phenyl, 2-chlorophenyl, 2-methylphenyl, 2- fluorophenyl, 2-bromophenyl, 3-chlorophenyl, 3-methylphenyl, 3-fluorophenyl, 3-bromophenyl,
• a further subvariant (variant e6) of the compounds according to variant e of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• a further subvariant (variant e7) of the compounds according to variant e of this invention includes those compounds of any of the formulae Ia, Ib, Ic, Id and Id', in which
• Rba is methyl, ethyl, fluorine or chlorine.
• a further subvariant (variant e8) of the compounds according to variant e of this invention includes those compounds of any of the formulae Ia, Ib, Ic, Id and Id', in which
• Rba is methyl, ethyl, fluorine or chlorine.
• a further subvariant (variant e9) of the compounds according to variant e of this invention includes those compounds of formula Ia or Ic, in which
• Rba is chlorine, methyl or ethyl.
• a further subvariant (variant e10) of the compounds according to variant e of this invention includes those compounds of formula Ia or Ic, in which
• Rba is chlorine, methyl or ethyl
• Rbb is fluorine, chlorine or methyl.
• a further subvariant (variant e11 ) of the compounds according to variant e of this invention includes those compounds of any of the formulae Ia and Ic, in which
• Rba is methyl, ethyl, fluorine or chlorine; especially, methyl, fluorine or chlorine.
• a further subvariant (variant e12) of the compounds according to variant e of this invention includes those compounds of any of the formulae Ia and Ic, in which
• Rba is methyl, ethyl, fluorine or chlorine; especially, methyl, fluorine or chlorine.
• a fifth embodimental variant (variant f) of the compounds of formula I according to this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which Q is optionally substituted by Rca and/or Rcb, and is Har, in which Har is a 5-membered monocyclic heteroaryl radical comprising one to four heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g.
• Har radical is attached to the parent molecular group via a ring carbon or ring nitrogen atom,
• Rca has one of the meanings as defined in the compounds mentioned above
• Rcb has one of the meanings as defined in the compounds mentioned above.
• a subvariant (variant f1 ) of the compounds according to variant f of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is optionally substituted by Rca and/or Rcb, and is Har, in which
• Har is furanyl, thiophenyl, imidazol-1-yl or pyrazol-1-yl,
• Rca is 1-4C-alkyl
• Rcb is 1-4C-alkyl.
• a further subvariant (variant f2) of the compounds according to variant f of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is furanyl, thiophenyl or dimethylfuranyl, such as e.g. furan-2-yl, thiophen-2-yl or 3,4- dimethylfuran-2-yl.
• a further subvariant (variant f3) of the compounds according to variant f of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is methyl-pyrazol-1-yl, such as e.g. 5-methyl-pyrazol-1-yl.
• a further subvariant (variant f4) of the compounds according to variant f of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is unsubstituted, and is furanyl or thiophenyl, such as e.g. furan-2-yl, furan-3-yl, thiophen-2-yl or thiophen-3-yl.
• a further subvariant (variant f5) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia, Ib, Ic, Id and Id', in which
• a further subvariant (variant f6) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia, Ib, Ic, Id and Id', in which
• Q is thiophenyl, such as e.g. thiophen-3-yl or, especially, thiophen-2-yl.
• a further subvariant (variant U) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia, Ib, Ic, Id and Id', in which
• Q is a radical of the following formula
• Rca is methyl or chlorine.
• a further subvariant (variant f8) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia, Ib, Ic, Id and Id', in which
• Q is a radical of the following formula
• Rca is methyl or chlorine
• Rcb is attached to any possible ring carbon atom, and is methyl.
• a further subvariant (variant f9) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia, Ib, Ic, Id and Id', in which
• Q is a radical of the following formula
• Rca is methyl or chlorine.
• a further subvariant (variant f10) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia, Ib, Ic, Id and Id', in which
• Q is a radical of the following formula which is attached to the parent molecular group via any possible ring carbon atom, and in which
• Rca is methyl or chlorine
• Rcb is attached to any possible ring carbon atom, and is methyl.
• a further subvariant (variant f11 ) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia and Ic, in which
• Rca is methyl or chlorine.
• a further subvariant (variant f12) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia and Ic, in which
• Rca is methyl or chlorine.
• a further subvariant (variant f13) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia and Ic, in which
• a further subvariant (variant f14) of the compounds according to variant f of this invention include those compounds of any of the formulae Ia and Ic, in which
• Q is thiophen-2-yl.
• a sixth embodimental variant (variant g) of the compounds of formula I according to this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is optionally substituted by Rca and/or Rcb, and is Har, in which
• Har is a 6-membered monocyclic heteroaryl radical comprising one or two nitrogen atoms, such as e.g. any one selected from pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl, whereby said Har radical is attached to the parent molecular group via a ring carbon atom,
• Rca has one of the meanings as defined in the compounds mentioned above,
• Rcb has one of the meanings as defined in the compounds mentioned above.
• a subvariant (variant g1) of the compounds according to variant g of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is optionally substituted by Rca and/or Rcb, and is Har, in which
• Rca has one of the meanings as defined in the compounds mentioned above,
• Rcb has one of the meanings as defined in the compounds mentioned above.
• a further subvariant (variant g2) of the compounds according to variant g of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Har is pyridinyl.
• a further subvariant (variant g3) of the compounds according to variant g of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is pyridin-3-yl.
• a further subvariant (variant g4) of the compounds according to variant g of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is pyridin-2-yl.
• a further subvariant (variant g5) of the compounds according to variant g of this invention include those compounds of formula Ia, in which
• Har is pyridin-2-yl.
• a further subvariant (variant g6) of the compounds according to variant g of this invention include those compounds of formula Ia, in which
• Har is pyridin-3-yl.
• a further subvariant (variant g7) of the compounds according to variant g of this invention include those compounds of formula Ic, in which
• Q is unsubstituted Har, in which Har is pyridin-2-yl.
• a further subvariant (variant g8) of the compounds according to variant g of this invention include those compounds of formula Ic, in which
• Har is pyridin-3-yl.
• a seventh embodimental variant (variant h) of the compounds of formula I according to this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is optionally substituted by Rda, and is Het, in which
• Het is a 3- to 7-membered monocyclic fully saturated heterocyclic ring comprising one or two heteroatoms independently selected from nitrogen, oxygen and sulphur, such as e.g. any one selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, homopiperazinyl, morpholinyl and thiomorpholinyl, whereby said Het radical is attached to the parent molecular group via a ring carbon or ring nitrogen atom,
• Rda has one of the meanings as defined in the compounds mentioned above.
• a subvariant (variant hi) of the compounds according to variant h of this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Het is tetrahydrofuranyl, such as e.g. tetrahydrofuran-2-yl.
• An eighth embodimental variant (variant i) of the compounds of formula I according to this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is unsubstituted, and is 3-7C-cycloalkyl, such as e.g. cyclohexyl.
• a ninth embodimental variant (variant j) of the compounds of formula I according to this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is attached via a carbon atom of the benzene ring to the parent molecular group, and is 1 ,3- benzodioxolyl, 2,2-difluoro-1 ,3-benzodioxolyl, 2,3-dihydro-1 ,4-benzodioxinyl, 2,3- dihydrobenzofuranyl, chromenyl or chromanyl.
• a tenth embodimental variant (variant k) of the compounds of formula I according to this invention includes those compounds of formulae Ia, Ib, Ic, Id or Id', in which
• Q is any one selected from the group consisting of phenyl, 2-chlorophenyl, 2-methylphenyl, 2- fluorophenyl, 2-bromophenyl, 3-chlorophenyl, 3-methylphenyl, 3-fluorophenyl, 3-bromophenyl,
• An eleventh embodimental variant (variant I) of the compounds of formula I according to this invention includes those compounds of any of the formulae Ia and Ic, in which
• Q is any one selected from the group consisting of 2-chlorophenyl, 2-methylphenyl, 2- fluorophenyl, 3-chlorophenyl, 3-methylphenyl, 3-fluorophenyl, furanyl, thiophenyl, such as e.g. furan-2-yl or thiophen-2-yl, and pyridinyl, such as e.g. pyridin-2-yl or pyridin-3-yl.
• the invention refers to all conceivable stereoisomers, like e.g. diastereomers and enantiomers, in substantially pure form as well as in any mixing ratio, including the racemates, as well as the salts thereof.
• enantiomerically pure compounds of this invention can be prepared according to art-known processes, such as e.g. via asymmetric syntheses, for example, by preparation and separation of appropriate diastereoisomeric compounds or by using chiral synthons or chiral reagents; by chromatographic separation on chiral separating columns; by means of salt formation of the racemic compounds with optically active acids or bases, subsequent resolution of the salts and release of the desired compound from the salt; by derivatization with chiral auxiliary reagents, subsequent diastereomer separation and removal of the chiral auxiliary group; or by (fractional) crystallization from a suitable solvent.
• art-known processes such as e.g. via asymmetric syntheses, for example, by preparation and separation of appropriate diastereoisomeric compounds or by using chiral synthons or chiral reagents; by chromatographic separation on chiral separating columns; by means of salt formation of the racemic compounds with optically active acids or bases,
• Exemplary compounds according to the present invention may include, without being restricted thereto, any compound selected from those compounds of formula I mentioned in the following examples, the enantiomers (e.g., when the compound is from formula Ic, in one special embodiment, the enantiomer having the formula Ic* and, in another special embodiment, the enantiomer having the formula Ic**) as well as the salts of these compounds and enantiomers.
• the enantiomers e.g., when the compound is from formula Ic, in one special embodiment, the enantiomer having the formula Ic* and, in another special embodiment, the enantiomer having the formula Ic**
• any or all of the following compounds of formula Ic, in which Ra is -C(O)ORI are more worthy to be mentioned by means of the substituent meanings for R1 and Q in the Table 1 given below, as well as the enantiomers and the salts of these compounds and enantiomers.
• a compound of formula III in which Ra has the meanings given above, can be condensed with malonitrile in the presence of sulfur and a suitable base, such as for example an amine (e.g. diethyl amine or morpholine) to give corresponding compounds of formula Il in a manner known to the person skilled in the art (e.g. according to a Gewald reaction) or as described in the following examples.
• a suitable base such as for example an amine (e.g. diethyl amine or morpholine) to give corresponding compounds of formula Il in a manner known to the person skilled in the art (e.g. according to a Gewald reaction) or as described in the following examples.
• compounds of the formula I can also be prepared from the corresponding compounds of formula Il and corresponding compounds of formula Rb-C(O)-X, in which X is hydroxyl, by reaction with amide bond linking reagents known to the person skilled in the art.
• amide bond linking reagents known to the person skilled in the art which may be mentioned are, for example, the carbodi- imides (e.g. dicyclohexylcarbodiimide or, preferably, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), azodicarboxylic acid derivatives (e.g. diethyl azodicarboxylate), uronium salts [e.g.
• preferred amide bond linking reagents are uronium salts and, particularly, carbodiimides, preferably, 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC).
• Acid derivatives of formula Rb-C(O)-X are known, commercially available or can be prepared as it is known for the skilled person, e.g. from the corresponding carboxylic acids.
• Carboxylic acids of formula Rb-C(O)-OH are known, commercially available or can be obtained as it is habitual for the skilled person, e.g. analogously or similarly to standard procedures.
• carboxylic acids of formula Rb-C(O)-OH in which Rb is -T-Q, in which T is 1-6C- alkylene, as defined above, especially those, in which Rb is -CH 2 -CH 2 -Q or -CH 2 -CH(CH 3 )-Q, in which Q has the meanings given above, can be obtained via CC-coupling reactions, such as e.g.
• carboxylic acids of formula Rb-C(O)-OH in which Rb is -T-Q, in which T is 1 ,2-cyclopropylene and Q has the meanings given above, can be obtained, starting from aldehydes of the formula Q-CHO, via Knoevenagel or Horner-Wadsworth-Emmons reaction, and then cyclopropanation reaction of the double bond (e.g. by Simmons-Smith reaction or, in particular, by Corey-Chaykovsky reaction using dimethylsulfoxonium methylide) and, if necessary, hydrolysis of the corresponding esters obtained.
• Compounds of formula IV can be converted into desired compounds of formula I by introduction of the group Ra via carbamate formation reaction.
• This carbamate formation reaction can be carried out analogously to the methods known to the person skilled in the art or as described by way of example in the following examples.
• the appropriate starting compounds for this carbamate formation reaction are art-known or can be obtained according to art-known procedures or analogously or similarly as disclosed for known compounds.
• Har-substituted alcohols in which Har has the meanings given above (e.g. substituted or unsubstituted pyridyl or imidazolyl), are used as starting compounds in the carbamate formation reaction, these alcohols can be obtained via CC-coupling reaction or nucleophilic substitution reaction of appropriate building blocks.
• Har-CH 2 -OH or Har-CH 2 -CH 2 -OH respectively, can be obtained from the corresponding heteroaromatic compounds by hydroxymethylation (e.g. metallation/reaction with formaldehyde) or hydroxyethylation (e.g. metallation/reaction with ethylene oxide) reaction, respectively.
• Aldehydes of the formula Har-CHO are known or can be obtained as it is known for the skilled person, such as e.g. from the corresponding heteroaromatic compounds by formylation reaction. Some aldehydes can be obtained as described e.g. for 4-methoxy-pyridin-2-carbaldehyde in Ashimori et al, Chem Pharm Bull 38, 2446-2458 (1990) or analogously or similarly thereto. It is to be understood for the skilled worker, that certain compounds of formula I according to this invention can be converted into further compounds of formula I by art-known synthesis strategies and reactions habitual per se to a person of ordinary skill in the art.
• compounds of formula I can be also converted into further compounds of formula I by methods known to one of ordinary skill in the art. More specifically, for example, from compounds of the formula I in which a) R2 is acyloxy, such as e.g. acetoxy, the corresponding free hydroxyl compounds can be obtained by removal of the acyl group, such as e.g. by saponification reaction; b) Het is a cyclic acetal or ketal, such as e.g. the 2,2-dimethyl-[1 ,3]dioxolan acetal, the corresponding free dihydroxy compounds can be obtained by cleavage of the acetal or ketal, such as e.g. by deacetalization reaction; c) R2 is an ester group, such as e.g. methoxycarbonyl, the corresponding free carboxyl compounds can be obtained by deesterification, such as e.g. by saponification reaction.
• acyloxy such as e.g. ace
• compounds of the formula I can be converted into their salts, or, optionally, salts of the compounds of the formula I can be converted into the free compounds.
• Corresponding processes are habitual per se to the skilled person.
• the substances according to the invention are isolated and purified in a manner known per se, for example by distilling off the solvent under reduced pressure and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as, for example, column chromatography on a suitable support material.
• Salts are obtained by dissolving the free compound in a suitable solvent (e.g. a ketone, such as acetone, methyl ethyl ketone or methyl isobutyl ketone, an ether, such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low-molecular- weight aliphatic alcohol, such as methanol, ethanol or isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added.
• a suitable solvent e.g. a ketone, such as acetone, methyl ethyl ketone or methyl isobutyl ketone, an ether, such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low-mol
• the present invention also relates to intermediates, including their salts, methods and processes useful in synthesizing compounds according to this invention.
• MS stands for mass spectrum
• M is the molecular ion in mass spectroscopy, calc. for calculated, fnd. for found, Boc for the tertbutoxycarbonyl group, EDC for 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride and other abbreviations have their meanings customary per se to the skilled person.
• (RS) characterizes a racemate comprising the one enantiomer having the configuration R and the other enantiomer having the configuration S; each of these enantiomers in pure form as well as their mixtures including the racemic mixtures is part of this invention.
• Diisopropyl ethyl amine (1.5 mmol) is added, the vial capped and the mixture is heated for 30 min at 150 0 C using microwave technology. Purification is achieved either by filtration followed by washing (water) and crystallization (ethanol) or removal of solvents in vacuo and subsequent column chromatography on silica gel, using mixtures of dichloromethane, methanol and triethyl amine as eluents.
• the following compounds can be prepared according to general procedure A starting either from 2- amino-3-cyano-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid ethyl ester (compound A1) or from 2-amino-3-cyano-4,7-dihydro-5H-thieno[2,3-c]pyridine-6-carboxylic acid tertbutyl ester (compound A2) and the appropriate art-known carboxylic acid.
• hydrocinnamic acid (1.5 mmol) is suspended in a mixture of DMF (0.15 mmol) and dichloromethane (7.5 mL).
• DMF 0.15 mmol
• dichloromethane 7.5 mL
• a solution of oxalyl chloride (3.0 mmol) in dichloromethane (7.5 mL) is then added and the mixture stirred for 1 h at room temperature.

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Virology (AREA)
• Oncology (AREA)
• AIDS & HIV (AREA)
• Tropical Medicine & Parasitology (AREA)
• Molecular Biology (AREA)
• Hematology (AREA)
• Communicable Diseases (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (6)

Applications Claiming Priority (6)

Related Child Applications (1)

Publications (1)

Family

ID=36146917

Family Applications (1)

Country Status (6)

Cited By (10)

Citations (1)

Family Cites Families (37)

• 2006
  • 2006-02-08 EP EP06708126A patent/EP1851229A1/en not_active Withdrawn
  • 2006-02-08 CA CA002596202A patent/CA2596202A1/en not_active Abandoned
  • 2006-02-08 JP JP2007553625A patent/JP2008529989A/ja active Pending
  • 2006-02-08 WO PCT/EP2006/050782 patent/WO2006084869A1/en not_active Ceased
  • 2006-02-08 AU AU2006212224A patent/AU2006212224A1/en not_active Abandoned
  • 2006-02-08 US US11/883,596 patent/US7714135B2/en not_active Expired - Fee Related
• 2009
  • 2009-03-26 US US12/411,486 patent/US20090227577A1/en not_active Abandoned
  • 2009-07-28 US US12/510,362 patent/US20100324038A1/en not_active Abandoned

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events